RAC 0.97% $1.54 race oncology ltd

Ann: Race Develops Improved IV Formulation of Zantrene, page-91

  1. 2,712 Posts.
    lightbulb Created with Sketch. 2824

    https://hotcopper.com.au/data/attachments/5813/5813763-ac5700bcefddab981d36c304dabc5c3b.jpg

    Intestine-penetrating, pH-sensitive and double-layered nanoparticles for oral delivery of doxorubicin with reduced toxicity
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.